3D Systems reports Q1 revenue of $95.5M, narrows loss By Investing.com

3D Systems reported Q1 revenue of $95.5 million, up 1% year over year, with GAAP loss per share narrowing to $0.03 from $0.28 and adjusted EBITDA turning positive at $2.1 million versus a $23.9 million loss. Healthcare Solutions revenue rose 21% to $50.1 million, helping gross margin improve to 35.9%, while Q2 guidance calls for revenue of $93 million-$95 million and adjusted EBITDA of negative $4 million to negative $2 million. The company also highlighted new dental and industrial product rollouts and EU medical device certifications that could support future growth.

Analysis

The real inflection here is not the headline margin bounce; it is that the business is starting to look like two very different companies. Healthcare is becoming the cash-flow stabilizer with recurring, regulated demand, while Industrial remains the cyclical drag that can mask operating leverage until capex confidence improves. That mix matters because the market will likely re-rate DDD less on absolute growth and more on whether the healthcare install base can offset the still-weak industrial pipeline over the next 2-3 quarters.

The second-order winner is the dental ecosystem: labs, material suppliers, and service bureaus that can adopt the jetted solution early should see faster throughput and lower labor intensity, which can widen their own margins before DDD fully scales monetization. The EU certification is the key catalyst because it converts a product story into a channel-access story; if shipments ramp without validation issues, Europe can become the first place where volume evidence overrides skepticism around prior software divestitures and product churn. Conversely, the 2026 debt maturity is small but not irrelevant because any stumble in Q2/Q3 guidance could quickly tighten equity optionality in a name trading largely on sentiment and turnaround credibility.

Consensus appears to be underestimating how fragile the improvement is relative to guidance. A positive EBITDA quarter is helpful, but the next leg requires sustained gross margin and a much cleaner industrial trend; otherwise, the stock can retrace quickly once investors realize the turnaround is still dependent on one segment and one geography. The stock has already moved hard year-to-date, so the risk/reward is no longer on the side of chasing strength without a catalyst that forces estimate revisions higher.

Key Decisions for Investors

• Avoid chasing DDD after the YTD move; use strength into the next 2-4 weeks to fade with a tight stop above recent highs, targeting a retrace if Q2 guidance fails to accelerate.
• For tactical upside, buy DDD Sep/Oct call spreads rather than outright equity: limited premium outlay, defined risk, and participation if EU commercialization or healthcare adoption drives a re-rating over the next 3-5 months.
• Pair trade: long a profitable dental/medical device beneficiary versus short DDD if you want exposure to the sector without turnaround risk; the relative value favors names with clearer recurring revenue and less execution variance.
• Watch the next two quarterly prints closely; if Industrial revenue keeps contracting and Healthcare growth decelerates, reduce or exit long exposure within 1-2 quarters because the equity story reverts to balance-sheet and dilution risk.
• If DDD pulls back on no new negative data, consider a small starter long for a 6-12 month hold, but size it as an event-driven turnaround trade rather than a fundamental compounder.